Not So Typical: Development of Atypical Chronic Myeloid Leukemia in a Patient With Chronic Myeloid Leukemia

Saba, Raya; Bhamidipati, Pavan Kumar; Cashen, Amanda F.

doi:10.1200/po.17.00186

Cited by 3 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic myeloid leukemia (CML) is a hematologic clonal malignancy that is produced by hematopoietic stem cells (HSC). [ 52 ] CML, a distinctive cytogenetic abnormality, involves the translocation of the Abelson oncogene 1 (ABL1) on chromosome 9, and breakpoint cluster region (BCR) on chromosome 22, t(9;22)(q34;q11.2), ensuing BCR-ABL gene union well-known Philadelphia positive (Ph+) chromosome [ 53 ]…”

Section: Chronic Myeloid Leukemiamentioning

confidence: 99%

“…Chronic Myeloid Leukemia Chronic myeloid leukemia (CML) is a hematologic clonal malignancy that is produced by hematopoietic stem cells (HSC). [52] CML, a distinctive cytogenetic abnormality, involves the translocation of the Abelson oncogene 1 (ABL1) on chromosome 9, and breakpoint cluster region (BCR) on chromosome 22, t(9;22)(q34;q11.2), ensuing BCR-ABL gene union well-known Philadelphia positive (Ph+) chromosome [53] Between 90% and 96%, Philadelphia positive (Ph+) chromosomes in CML were detected. By altering the (3' to 5') segment of the ABL oncogene (9q34) and BCR gene (22q11.2), respectively, the BCR-ABL fusion gene, which encodes a constitutive TK active oncoprotein.…”

Section: Sars-cov-2: Preventionmentioning

confidence: 99%

See 1 more Smart Citation

Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review

et al. 2022

View full text Add to dashboard Cite

Severe acute respiratory syndrome (SARS) caused by a novel coronavirus-2 (CoV-2), also known as COVID-19, has spread rapidly worldwide since it is recognized as a public health emergency and has now been declared a pandemic on March 11, 2020, by the World Health Organization. The genome of SARS-CoV-2 comprises a single-stranded positive-sense RNA approximately 27 to 30 kb in size. The virus is transmitted through droplets from humans to humans. Infection with the SARS virus varies from asymptomatic to lethal, such as fever, cough, sore throat, and headache, but in severe cases, pneumonia and acute respiratory distress syndrome. Recently, no specific and effective treatment has been recommended for patients infected with the SARS virus. However, several options can be investigated to control SARS-CoV-2 infection, including monoclonal antibodies, interferons, therapeutic vaccines, and molecular-based targeted drugs. In the current review, we focus on tyrosine kinase inhibitor management and their protective role in SARS-CoV-2 patients with chronic myelogenous leukemia.

show abstract

Section: Chronic Myeloid Leukemiamentioning

confidence: 99%

Section: Sars-cov-2: Preventionmentioning

confidence: 99%

Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…4,7,11,12 Increased total leukocyte count (>50 × 10 9 /l), increased percentage of immature white blood cells, hemoglobin level <10gm/dl, age > 65 years, and presence of three or more chromosome mutations have been linked to decreased morbidity and mortality. 2,13,14 In 20 to 40% cases of aCML, they evolve to acute myeloid leukaemia (AML) within 18 months of diagnosis. 4,15 Certain predisposing factors such as enlarged liver or spleen, elevated levels of monocytes (>3 × 10 9 /l but <8 × 10 9 /l), >5% of blasts in the bone marrow have been linked to the increased chances of progression to AML.…”

Section: Introductionmentioning

confidence: 99%

Hydroxyurea- a cost effective treatment in developing countries for Atypical Chronic Myeloid Leukemia (aCML): Case Report of Two Patients

Hassan

Iqbal

Zahoor

et al. 2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Atypical chronic myeloid leukaemia (aCML) is a rare chronic myeloproliferative disorder with a poor prognosis. Case report This case report presents two cases of male geriatric patients, both referred from primary care in rural areas and received at an urban clinic in a tertiary care hospital on separate instances. The first patient complained of low-grade fever (on/off), generalized body aches, rapid weight loss and shortness of breath for the last 2 months. The second patient arrived pale looking with symptoms of generalized body aches, dizziness and anorexia. Both patients were diagnosed to have aCML according to the World Health organization criteria. Management & outcome Both the patients were from a low economic bracket and were treated with Hydroxyurea a relatively economic medicine successfully. The follow-up lasted for 12 months in both cases. No progression to acute myeloid leukaemia (AML) or relapse was observed. Discussion This case report shows the promising results of Hydroxyurea in treating aCML and can be a cost effective alternate to other expensive treatments (allogeneic hematopoietic stem cell transplantation) and expensive medicines in lower and middle-income countries especially for resource-limited patients. These two cases show promising evidence for further studies to evaluate and conduct pharmaco-economic evaluations as well as clinical trials to compare hydroxyurea with other available alternative treatments for an affordable therapeutic option towards prevention of relapse and disease free survival after aCML.

show abstract

Hydroxycarbamide/imatinib

2018

Reactions Weekly

View full text Add to dashboard Cite

Not So Typical: Development of Atypical Chronic Myeloid Leukemia in a Patient With Chronic Myeloid Leukemia

Cited by 3 publications

References 27 publications

Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review

Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review

Hydroxyurea- a cost effective treatment in developing countries for Atypical Chronic Myeloid Leukemia (aCML): Case Report of Two Patients

Hydroxycarbamide/imatinib

Contact Info

Product

Resources

About